ProCE Banner Activity

Understanding Evolving Adjuvant Treatment Approaches for HER2-Positive Breast Cancer

Clinical Thought
Adjuvant treatment for HER2+ EBC is evolving with new agents and potentially practice-changing clinical trial data. Read my thoughts on how I am using these new findings in my clinical practice.

Released: April 12, 2018

Expiration: April 11, 2019

No longer available for credit.

Share

Faculty

Joyce O’Shaughnessy

Joyce O’Shaughnessy, MD

Co-Director, Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
Texas Oncology
US Oncology
Dallas, Texas

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

This activity is supported by an educational grant from

Genentech TEXT Only

Partners

GRACE

ProCE Banner

Faculty Disclosure

Primary Author

Joyce O’Shaughnessy, MD

Co-Director, Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
Texas Oncology
US Oncology
Dallas, Texas